Faculty profile

Mark Bosch

Back to faculty

Associate ProfessorHematological OncologyUniversity of Saskatchewan

Mark Bosch

Associate Professor

Hematological Oncology

College of Medicine

University of Saskatchewan

Saskatoon, Saskatchewan, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
5 publications in the last five years, latest in 2026.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

116

Citations

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their University of Saskatchewan profile.

Stem Cell Transplant CAR T Immunotherapy

Latest papers

Canadian Hematology Consensus Group Recommendations for the Management of Relapsed and/or Refractory Follicular Lymphoma.
Current oncology (Toronto, Ont.) · 2026
Safety and efficacy of G-CSF alone with pre-emptive plerixafor for autologous peripheral blood hematopoietic stem cell mobilization in newly diagnosed multiple myeloma.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2026
CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8+CD103+ cDC1 and TRM cell responses.
Cancer immunology, immunotherapy : CII · 2025

All 10 publications

Latest funding

Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
CIHR · 2022 · Co-investigator
$3,216,843
Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)
CIHR · 2022 · Co-investigator
$804,211

All 2 grants and awards

10 publications.

Canadian Hematology Consensus Group Recommendations for the Management of Relapsed and/or Refractory Follicular Lymphoma.

Owen C, Lemieux C, Bosch M, Davison K, Forward N, Kanasara R, Keating MM, Prica A, Stewart C, Vijenthira A, Sehn LH

Current oncology (Toronto, Ont.)2026

DOI: 10.3390/curroncol33080451 PMID: 42645356

Safety and efficacy of G-CSF alone with pre-emptive plerixafor for autologous peripheral blood hematopoietic stem cell mobilization in newly diagnosed multiple myeloma.

Elemary Y, Sabry W, Stakiw J, Bosch M, Goubran H, Sanayei J, Kodad S, MacKay R, Lacey J, Sarker S, Elemary M

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2026

DOI: 10.1016/j.transci.2025.104304 PMID: 41443057

CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8+CD103+ cDC1 and TRM cell responses.

Wu Z, Yang Z, Iftikhar T, Groot G, Leary SC, Baniak N, Ahmed S, Bosch M, Moser M, Zhang W, Jiang J, Xiang J

Cancer immunology, immunotherapy : CII2025Open Access

DOI: 10.1007/s00262-025-04217-7 PMID: 41251836

Validation of next-generation sequencing-based chimerism testing for accurate detection and monitoring of engraftment in hematopoietic stem cell transplantation.

Kakodkar P, Zhao Y, Pan H, Wu F, Pearce T, Webster D, Elemary M, Sabry W, Kwan L, Pelzer L, Bosch M, Sherwood KR, Lan J, Tran J, Liwski R, Keown P, Mostafa A

Frontiers in genetics202313 citationsOpen Access

DOI: 10.3389/fgene.2023.1282947 PMID: 37937195

DDX41 is required for cGAS-STING activation against DNA virus infection.

Singh RS, Vidhyasagar V, Yang S, Arna AB, Yadav M, Aggarwal A, Aguilera AN, Shinriki S, Bhanumathy KK, Pandey K, Xu A, Rapin N, Bosch M, DeCoteau J, Xiang J, Vizeacoumar FJ, Zhou Y, Misra V, Matsui H, Ross SR, Wu Y

Cell reports202285 citationsOpen Access

DOI: 10.1016/j.celrep.2022.110856 PMID: 35613581

BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.

Hahn L, Lim H, Dusyk T, Sabry W, Elemary M, Stakiw J, Danyluk P, Bosch M

Scientific reports2021Senior author

DOI: 10.1038/s41598-021-93516-x PMID: 34234243

Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption.

Aggarwal V, Sabry W, Elemary M, Bosch M, Danyluk P, Mondal P, Stakiw J

Current oncology (Toronto, Ont.)2021

DOI: 10.3390/curroncol28030148 PMID: 33922026

A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.

Bosch M, Akhter A, Chen BE, Mansoor A, Lebrun D, Good D, Crump M, Shepherd L, Scott DW, Stewart DA

Haematologica201818 citationsFirst authorOpen Access

DOI: 10.3324/haematol.2017.179309 PMID: 29097500

Transfusion challenges in hematology oncology and hematopoietic stem cell transplant - Literature review and local experience.

Elemary M, Seghatchian J, Stakiw J, Bosch M, Sabry W, Goubran H

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2017

DOI: 10.1016/j.transci.2017.05.022 PMID: 28642120

Short nucleotide polymorphic insertions in the MCL-1 promoter affect gene expression.

Saxena A, Moshynska OV, Moshynskyy ID, Neuls ED, Qureshi T, Bosch M, Voralia M, Bonham K

Cancer letters2007

DOI: 10.1016/j.canlet.2006.11.007 PMID: 17198743

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

Mark Bosch

Research

Latest papers

Latest funding

Canadian Hematology Consensus Group Recommendations for the Management of Relapsed and/or Refractory Follicular Lymphoma.

Safety and efficacy of G-CSF alone with pre-emptive plerixafor for autologous peripheral blood hematopoietic stem cell mobilization in newly diagnosed multiple myeloma.

CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8+CD103+ cDC1 and TRM cell responses.

Validation of next-generation sequencing-based chimerism testing for accurate detection and monitoring of engraftment in hematopoietic stem cell transplantation.

DDX41 is required for cGAS-STING activation against DNA virus infection.

BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.

Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption.

A bioclinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.

Transfusion challenges in hematology oncology and hematopoietic stem cell transplant - Literature review and local experience.

Short nucleotide polymorphic insertions in the MCL-1 promoter affect gene expression.

Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)

Paving The Way to a Canadian Standard of Care with CAR-T Cellular Therapy: Phase II Trial of CD19 CAR-T for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia (CLIC-01A)

Frequent collaborators

Mohamed Elemary

Waleed Sabry

Jim Xiang

Yayuan Zhao

Anurag Saxena

David LeBrun

Franco Vizeacoumar

Paul Keown

Shahid Ahmed

Yan Zhou

Gary Groot

David Scott

Wenjun Zhang

Bingshu Chen

Vikram Misra

Yuliang Wu

David Good

Lois Shepherd

Michael Crump

Ahmed Mostafa

John DeCoteau

Scot Leary

Michael Moser